Nanobiotix reports 79% one-year control in lung-cancer study, €110.9 million cash
AI Summary- Nanobiotix reported clinical and financial progress for the first half of 2026.
- 79% was the one-year locoregional control rate in its 24-patient Phase 1 NSCLC study.
- Nanobiotix completed an approximately €86 million follow-on offering in May 2026.